awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33400687-417BE244-B398-4DA6-AC56-2F6407051329
Q33400687-417BE244-B398-4DA6-AC56-2F6407051329
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-417BE244-B398-4DA6-AC56-2F6407051329
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
P2888
Q33400687-417BE244-B398-4DA6-AC56-2F6407051329
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-417BE244-B398-4DA6-AC56-2F6407051329
rank
NormalRank
type
BestRank
Statement
P2888
s10637-012-9815-9